Newly-released cell therapy market analysis report by Transparency Market Research shows that global sales of the Market in 2021 were held at US$ 8.5 Bn. With 18.7%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Autologous Therapies of cell therapy are expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 18% from 2022 – to 2032.
As per the Market research by Transparency Market Research - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Market increased at around 16% CAGR.
Cell and gene therapy-based products have the potential to be a viable and disease-modifying treatment for diseases that would otherwise be incurable with conventional medicines. Another factor driving market expansion is the increased usage of cell therapy products in hospitalized patients to treat burns, venous leg ulcers, diabetic foot ulcers, traumas, and pressure ulcers. According to the American College of Surgeons, 1–2% of the worldwide population will develop chronic wounds over their lives.
As per the Centre for Disease Control and Prevention (CDC), six out of ten individuals in the United States have a chronic disease, and four out of ten persons have two or more chronic diseases. As a result, the demand for various cellular treatments, such as transfusion, immune cell therapy, and stem cell therapy, among others, is increasing among healthcare professionals.
According to statistics from the American National Red Cross, around 21 million blood transfusions are transfused in the United States each year. Furthermore, according to the Health Resources and Services Administration (HSRA), there were 4992 unconnected and 4275 related bone marrow and umbilical cord blood transplants in the United States in 2018.
Cell and gene therapies (CGTs) are at the cutting edge of technology in the treatment of both severe and uncommon illnesses. LUXTURNA, a therapy for a hereditary retinal illness that causes blindness, is one of several such medicines presently on the market.
CGT marks a prominent medical breakthrough as it was the first curative gene therapy to be licensed for use. In August 2020, the FDA approved Novartis' Kymriah regenerative medicine for improved therapy in the treatment of adult patients with refractory follicular lymphoma. In July 2020, the FDA approved brexucabtagene Acelus, a CAR T-cell treatment for patients with mantle cell lymphoma.
Many additional CGTs are currently being developed. As of June 2020, more than 750 CGT studies in about 30,000 patients were underway, and CGT drugs represent approximately 12% of the pharmaceutical industry's clinical pipeline and at least 16% of its preclinical pipeline. The general need for novel, more effective treatments like cancer therapy and cardiovascular disease has spurred research into solutions via cell-based research, whereas the Australian government released a new Cell Therapies Mission in November 2019.
Under the Medical Research Future Fund (MRFF), the project would provide US$ 102 million to incentivize stem cell research to develop novel medicines. Similarly, Foster innovation UK, the UK's technology agency was awarded GBP 267,000 in financing in September 2019 to foster gel stabilization technology created by Atelerix, with the first goal of winning.
The majority of medicinal cell manufacturing procedures have been designed using a cell biology-driven strategy, which is critical in the early stages of research. However, for reliable and standardized production in a maturing area, a highly regulated manufacturing engineering plan with automation, process monitoring, and control to improve batch efficiency and consistency is required.
Over 900 companies are now committed to the study and manufacture of cell-based medicinal products, ranging from small and medium-sized businesses to international organizations.
To create cells in volumes that match therapeutic demands, a scalable method for multipotent cell growth and differentiation is necessary. Aside from quantity, the manufacturing method must adhere to good manufacturing principles (GMP) and enable the culture to be performed under controlled, serum-free, and Xeno-free conditions. In scalability, simplicity of design, and ease of handling, cell culture in bioreactors is the most advantageous culture option for large manufacturing.
In 2021, North America held the largest share of the global cancer therapy market. Government support for the healthcare sector's development, a high level of awareness about rare disorders, easy access to high-quality medical facilities, and reimbursement policies are some of the key drivers for regional market growth.
Between 2013 and 2017, there were 75,497 new cases of MDS Myelodysplastic Syndromes in North America, with an average of 15,099 cases each year. In North America, an estimated 58,471 persons have MDS or are in remission. MDS has a 5-year relative survival rate of 38.3% from 2010 to 2016.
One in every three individuals has more than one chronic ailment or many chronic conditions. Cell therapy developers are being supported by both the public and business sectors. In terms of R&D activity and financing to develop and market cell and gene therapy products, North America is at the forefront.
For example, the Alliance for Cancer Gene Therapy provides Young Investigator and Clinical Translation funding ranging from US$ 250,000 to US$ 500,000 over a period of three to five years, with a maximum limit of 10 indirect expenses. The California Institute of Regenerative Medicine and the National Heart, Lung, and Blood Institute formed a partnership in May 2019, co-funded, and expedite the discovery of cancer treatments.
The United States is at the forefront of research in biomedical and technological advancement. Someone in the United States suffers from a blood malignancy every 9 minutes. This figure equates to nearly 158 individuals each day or more than six people per hour. In the United States, leukemia, lymphoma, and myeloma are anticipated to kill 57,750 individuals in 2021.
Based on a projected total of 608,570 cancer deaths, these illnesses are predicted to account for 9.5% of cancer deaths in 2021. The United States has been a driving force behind the development of a stem cell and cell-based therapeutic 'tourist' sector.
It is estimated that 350 stem cell clinics for chronic illnesses like leukemia throughout the world receive an average of five tourists per month, resulting in 21,000 stem cell and cell therapy medical tourists every year out of a total of 3,000,000 medical tourists. This accounts for around 0.7% of the total medical travel patient flow and about 3% of overall revenue.
The market for cell therapy in the U.K. is expected to reach a valuation of US$ 2.2 Bn by 2032. With a CAGR of 21.4% during 2022 – 2032, the market is expected to gross an absolute dollar opportunity of around US$ 2 Bn.
In Japan, the market for cell therapy grew at a CAGR of 16.7% during 2017 – 2021. The market is expected to reach a valuation of US$ 2.5 Bn, growing at a CAGR of 20.5%. The market is expected to gross an absolute dollar opportunity of US$ 2.1 Bn during the forecast period.
The market for cell therapy in South Korea is expected to reach a valuation of US$ 1 Bn by 2032. Growing at a CAGR of 18% during the forecast period, the market is projected to gross an absolute dollar opportunity of US$ 823 Mn.
The research-use type of cell therapy market accounted for a CAGR of 18.2% of total revenue in the forecast period. Research initiatives are the ones that most accounted for stem cells, which resulted in a substantial revenue share for the research-use sector. Several stem cell-based therapies have been licensed for clinical studies by the Food and Drug Administration (FDA).
According to a 2013 study from the Pharmaceutical Research and Manufacturers of America, 69 cell treatments are undergoing FDA clinical trials, with 15 of them in phase 3. Cardiovascular disease, skin illnesses, cancer, and associated ailments, digestive problems, transplant, genetic problems, musculoskeletal disorders, and eye issues are among the therapeutic categories covered in these studies.
Autologous Therapies commanded the largest revenue as well as a CAGR of 18.2%, during the forecast period. Autologous fat grafts were used for aesthetic purposes for over a century. Severe, partial, and filled burns have all been treated with autologous keratinocytes. Autologous human fibroblasts are beneficial in the treatment of wrinkles, rhytids, and acne scars.
These cells are in charge of the extracellular environment's production and secretion (collagen, elastin, hyaluronic acid, and glycosaminoglycans) and, when injected, may detect and restore self-diminished regions in the dermis.
Some of the key companies operating in the cell therapy market include Novartis AG, Pharmicell, Osiris Therapeutics (Smith & Nephew), GlaxoSmithKline, Anterogen, IMFS, Stemedica Cell Technologies, NuVasive, BioNTech, Kolon TissueGene, JCR Pharmaceuticals, Cells for Cells, and Vericel Corporation.
Some of the recent developments of key cell therapy providers are as follows:
Similarly, recent developments related to companies in Cell Therapy services have been tracked by the team at Transparency Market Research, which is available in the full report.
By Use Type
By Therapy Type
By Region
|
Attribute |
Details |
|
Global Cell Therapy Market (2022) |
US$ 10 Bn |
|
Global Cell Therapy Industry (2032) |
US$ 54.6 Bn |
|
Global Market CAGR (2022 – 2032) |
18.7% |
|
U.S. Cell Therapy Market CAGR (2022 – 2032) |
18.3% |
|
Key Companies Profiled |
|
The global Market is worth more than US$ 8.5 Bn at present.
The value of Market is projected to increase at a CAGR of around 18.7% from 2022 – to 2032.
The value of the Market increased at a CAGR of around 16% from 2017 – to 2021.
Continuous advances in cell therapy have led to the use of several types of stem cells in the treatment of a wide range of disorders, including dendritic cells, mesenchymal stem cells, skeletal muscle stem cells, hematopoietic stem cells, and lymphocytes.
The market for Cell Therapy in China is projected to expand at a CAGR of around 20.8% from 2022 – to 2032.
While the market in South Korea is expected to grow at nearly 18%, the market in Japan is projected to register a CAGR of nearly 20.5% from 2022 – to 2032.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Cell Therapy Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Use-type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Use-type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Use-type, 2022-2032
5.3.1. Clinical-use
5.3.1.1. Therapeutic Area
5.3.1.2. Cell Type
5.3.2. Research-use
5.4. Y-o-Y Growth Trend Analysis By Use-type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Use-type, 2022-2032
6. Global Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032
6.3.1. Allogenic Therapies
6.3.2. Autologous Therapies
6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032
7. Global Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Use-type
8.2.3. By Therapy Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Use-type
8.3.3. By Therapy Type
8.4. Key Takeaways
9. Latin America Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Use-type
9.2.3. By Therapy Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Use-type
9.3.3. By Therapy Type
9.4. Key Takeaways
10. Europe Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Russia
10.2.1.7. Rest of Europe
10.2.2. By Use-type
10.2.3. By Therapy Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Use-type
10.3.3. By Therapy Type
10.4. Key Takeaways
11. Asia Pacific Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. India
11.2.1.4. South Korea
11.2.1.5. Australia
11.2.1.6. Rest of APAC
11.2.2. By Use-type
11.2.3. By Therapy Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Use-type
11.3.3. By Therapy Type
11.4. Key Takeaways
12. Middle East and Africa Cell Therapy Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. South Africa
12.2.1.2. Saudi Arabia
12.2.1.3. UAE
12.2.1.4. Israel
12.2.1.5. Rest of MEA
12.2.2. By Use-type
12.2.3. By Therapy Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Use-type
12.3.3. By Therapy Type
12.4. Key Takeaways
13. Key Countries Cell Therapy Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Use-type
13.1.2.2. By Therapy Type
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Use-type
13.2.2.2. By Therapy Type
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Use-type
13.3.2.2. By Therapy Type
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Use-type
13.4.2.2. By Therapy Type
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Use-type
13.5.2.2. By Therapy Type
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Use-type
13.6.2.2. By Therapy Type
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Use-type
13.7.2.2. By Therapy Type
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Use-type
13.8.2.2. By Therapy Type
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Use-type
13.9.2.2. By Therapy Type
13.10. Russia
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Use-type
13.10.2.2. By Therapy Type
13.11. China
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Use-type
13.11.2.2. By Therapy Type
13.12. Japan
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Use-type
13.12.2.2. By Therapy Type
13.13. India
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Use-type
13.13.2.2. By Therapy Type
13.14. South Korea
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Use-type
13.14.2.2. By Therapy Type
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Use-type
13.15.2.2. By Therapy Type
13.16. South Africa
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Use-type
13.16.2.2. By Therapy Type
13.17. Saudi Arabia
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Use-type
13.17.2.2. By Therapy Type
13.18. UAE
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Use-type
13.18.2.2. By Therapy Type
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Use-type
13.19.2.2. By Therapy Type
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Use-type
14.3.3. By Therapy Type
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Kolon TissueGene, Inc.
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. JCR Pharmaceuticals Co., Ltd.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Medipost Co Ltd
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Smith & Nephew
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Stemedica Cell Technologies, Inc.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. NuVasive, Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Castle Creek Biosciences, Inc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Vericel Corporation
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Pharmicell
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Anterogen Co Ltd
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. Bristol-Myers Squibb Company
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
List of Tables
Table 1: Global Cell Therapy Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Cell Therapy Market Value (US$ Mn) Forecast by Use-type, 2017-2032
Table 3: Global Cell Therapy Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 4: North America Cell Therapy Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 5: North America Cell Therapy Market Value (US$ Mn) Forecast by Use-type, 2017-2032
Table 6: North America Cell Therapy Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 7: Latin America Cell Therapy Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: Latin America Cell Therapy Market Value (US$ Mn) Forecast by Use-type, 2017-2032
Table 9: Latin America Cell Therapy Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 10: Europe Cell Therapy Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 11: Europe Cell Therapy Market Value (US$ Mn) Forecast by Use-type, 2017-2032
Table 12: Europe Cell Therapy Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 13: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast by Use-type, 2017-2032
Table 15: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 16: Middle East and Africa Cell Therapy Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: Middle East and Africa Cell Therapy Market Value (US$ Mn) Forecast by Use-type, 2017-2032
Table 18: Middle East and Africa Cell Therapy Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
List of Figures
Figure 1: Global Cell Therapy Market Value (US$ Mn) by Use-type, 2022-2032
Figure 2: Global Cell Therapy Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 3: Global Cell Therapy Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Cell Therapy Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Cell Therapy Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Cell Therapy Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Cell Therapy Market Value (US$ Mn) Analysis by Use-type, 2017-2032
Figure 8: Global Cell Therapy Market Value Share (%) and BPS Analysis by Use-type, 2022-2032
Figure 9: Global Cell Therapy Market Y-o-Y Growth (%) Projections by Use-type, 2022-2032
Figure 10: Global Cell Therapy Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 11: Global Cell Therapy Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 12: Global Cell Therapy Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 13: Global Cell Therapy Market Attractiveness by Use-type, 2022-2032
Figure 14: Global Cell Therapy Market Attractiveness by Therapy Type, 2022-2032
Figure 15: Global Cell Therapy Market Attractiveness by Region, 2022-2032
Figure 16: North America Cell Therapy Market Value (US$ Mn) by Use-type, 2022-2032
Figure 17: North America Cell Therapy Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 18: North America Cell Therapy Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Cell Therapy Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 20: North America Cell Therapy Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Cell Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Cell Therapy Market Value (US$ Mn) Analysis by Use-type, 2017-2032
Figure 23: North America Cell Therapy Market Value Share (%) and BPS Analysis by Use-type, 2022-2032
Figure 24: North America Cell Therapy Market Y-o-Y Growth (%) Projections by Use-type, 2022-2032
Figure 25: North America Cell Therapy Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 26: North America Cell Therapy Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 27: North America Cell Therapy Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 28: North America Cell Therapy Market Attractiveness by Use-type, 2022-2032
Figure 29: North America Cell Therapy Market Attractiveness by Therapy Type, 2022-2032
Figure 30: North America Cell Therapy Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Cell Therapy Market Value (US$ Mn) by Use-type, 2022-2032
Figure 32: Latin America Cell Therapy Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 33: Latin America Cell Therapy Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Cell Therapy Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 35: Latin America Cell Therapy Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Cell Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Cell Therapy Market Value (US$ Mn) Analysis by Use-type, 2017-2032
Figure 38: Latin America Cell Therapy Market Value Share (%) and BPS Analysis by Use-type, 2022-2032
Figure 39: Latin America Cell Therapy Market Y-o-Y Growth (%) Projections by Use-type, 2022-2032
Figure 40: Latin America Cell Therapy Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 41: Latin America Cell Therapy Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 42: Latin America Cell Therapy Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 43: Latin America Cell Therapy Market Attractiveness by Use-type, 2022-2032
Figure 44: Latin America Cell Therapy Market Attractiveness by Therapy Type, 2022-2032
Figure 45: Latin America Cell Therapy Market Attractiveness by Country, 2022-2032
Figure 46: Europe Cell Therapy Market Value (US$ Mn) by Use-type, 2022-2032
Figure 47: Europe Cell Therapy Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 48: Europe Cell Therapy Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Cell Therapy Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 50: Europe Cell Therapy Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Cell Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Cell Therapy Market Value (US$ Mn) Analysis by Use-type, 2017-2032
Figure 53: Europe Cell Therapy Market Value Share (%) and BPS Analysis by Use-type, 2022-2032
Figure 54: Europe Cell Therapy Market Y-o-Y Growth (%) Projections by Use-type, 2022-2032
Figure 55: Europe Cell Therapy Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 56: Europe Cell Therapy Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 57: Europe Cell Therapy Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 58: Europe Cell Therapy Market Attractiveness by Use-type, 2022-2032
Figure 59: Europe Cell Therapy Market Attractiveness by Therapy Type, 2022-2032
Figure 60: Europe Cell Therapy Market Attractiveness by Country, 2022-2032
Figure 61: Asia Pacific Cell Therapy Market Value (US$ Mn) by Use-type, 2022-2032
Figure 62: Asia Pacific Cell Therapy Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 63: Asia Pacific Cell Therapy Market Value (US$ Mn) by Country, 2022-2032
Figure 64: Asia Pacific Cell Therapy Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 65: Asia Pacific Cell Therapy Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: Asia Pacific Cell Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: Asia Pacific Cell Therapy Market Value (US$ Mn) Analysis by Use-type, 2017-2032
Figure 68: Asia Pacific Cell Therapy Market Value Share (%) and BPS Analysis by Use-type, 2022-2032
Figure 69: Asia Pacific Cell Therapy Market Y-o-Y Growth (%) Projections by Use-type, 2022-2032
Figure 70: Asia Pacific Cell Therapy Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 71: Asia Pacific Cell Therapy Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 72: Asia Pacific Cell Therapy Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 73: Asia Pacific Cell Therapy Market Attractiveness by Use-type, 2022-2032
Figure 74: Asia Pacific Cell Therapy Market Attractiveness by Therapy Type, 2022-2032
Figure 75: Asia Pacific Cell Therapy Market Attractiveness by Country, 2022-2032
Figure 76: Middle East and Africa Cell Therapy Market Value (US$ Mn) by Use-type, 2022-2032
Figure 77: Middle East and Africa Cell Therapy Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 78: Middle East and Africa Cell Therapy Market Value (US$ Mn) by Country, 2022-2032
Figure 79: Middle East and Africa Cell Therapy Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 80: Middle East and Africa Cell Therapy Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: Middle East and Africa Cell Therapy Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: Middle East and Africa Cell Therapy Market Value (US$ Mn) Analysis by Use-type, 2017-2032
Figure 83: Middle East and Africa Cell Therapy Market Value Share (%) and BPS Analysis by Use-type, 2022-2032
Figure 84: Middle East and Africa Cell Therapy Market Y-o-Y Growth (%) Projections by Use-type, 2022-2032
Figure 85: Middle East and Africa Cell Therapy Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 86: Middle East and Africa Cell Therapy Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 87: Middle East and Africa Cell Therapy Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 88: Middle East and Africa Cell Therapy Market Attractiveness by Use-type, 2022-2032
Figure 89: Middle East and Africa Cell Therapy Market Attractiveness by Therapy Type, 2022-2032
Figure 90: Middle East and Africa Cell Therapy Market Attractiveness by Country, 2022-2032
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cell Therapy Market
